Biomarkers in Oncology: Prediction and Prognosis by Armin Gerger M.D., Melissa J. LaBonte Ph.D. (auth.),

By Armin Gerger M.D., Melissa J. LaBonte Ph.D. (auth.), Heinz-Josef Lenz (eds.)

This built-in ebook covers the whole spectrum of melanoma biomarkers in improvement and medical use. Predictive and prognostic markers are explored within the context of colon melanoma, breast melanoma, lung melanoma, prostate melanoma, and GIST. overseas specialists offer perception into toxicity markers and surrogate markers. realization is additionally given to biomarker assay improvement, validation, and techniques.

A strong instrument for deciding on judgements on remedy, picking drug regimens, tracking the efficacy of remedy, and appearing individualized surveillance, biomarkers symbolize the leading edge of melanoma examine and remedy. As those applied sciences turn into more and more to be had for scientific use, this ebook may be a necessary source for oncologists and translational researchers.

Show description

Read Online or Download Biomarkers in Oncology: Prediction and Prognosis PDF

Best nonfiction_10 books

Hemostasis and Circulation

Current study at the courting among thrombosis and flow is amassed during this quantity. uncomplicated and medical experiences of thrombosis, fibrinolysis and platelets are said. specifically, new proteins present in leeches or snakes that may be used to regard or hinder thrombosis are mentioned.

Histocompatibility Antigens: Structure and Function

The key Histocompatibility advanced (MHC) was once came across as a con­ series of the power challenge encountered via melanoma biologists within the early years of this century: the failure to take care of tumor traces via serial passage in outbred mice. a few observations pointed to genetic similarity being a prerequisite for profitable transplantation and so they have been included right into a genetic conception of transplantation by way of C.

Leonard Wood and Cuban Independence 1898–1902

This can be a learn of the army govt of Cuba from 1898 to 1902. Tracing and explaining the activities of basic Leonard Wood's adminis­ tration in the course of these years unearths how the us govt re­ solved the questions of independence, strategic defense, and financial inter­ ests in regard to Cuba.

Therapeutic Interventions in the Complement System

Even supposing the supplement approach is a crucial a part of the body's defenses opposed to micro organism, its beside the point activation produces the mobilephone harm present in a wide selection of health problems, starting from hemolytic anemia to a number of sclerosis. In healing Interventions within the supplement method, a staff of professional investigators and researchers comprehensively assessment complement's uncomplicated biology, its position in disorder, the way to degree its task, and methods for its inhibition in sufferers.

Extra info for Biomarkers in Oncology: Prediction and Prognosis

Example text

2010;15:390–404. 10. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 2010;36:550–6. 11. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–5. 12. Allegra CJ, Jessup JM, Somerfield MR, et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

J Clin Oncol. 2001;19:2010–9. 22. Lackowska B, Niezabitowski A, Rys J, et al. S-phase fraction and menopausal status as the most important prognostic factors of disease-free survival for node negative patients with breast cancer: a prospective study. Pol J Pathol. 2003;54:101–10. 23. Pinto AE, Andre S, Soares J. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol. 1999;52:604–11.

1 summarizes the prognostic and predictive markers for breast cancer that have been well validated and have demonstrated clinical value. The guidelines and recommendations from the American Society of Clinical Oncology (ASCO) for the use of makers in breast cancer are [27]: • ER, PR, should be evaluated on every primary breast cancer and used to guide endocrine therapy decisions. • HER2 overexpression should be evaluated on every primary breast cancer and used to guide trastuzumab in metastatic and adjuvant setting.

Download PDF sample

Rated 4.63 of 5 – based on 43 votes